Dr. Charles Erlichman is a Professor of Oncology in the Mayo Clinic College of Medicine and Chairman of the Department of Oncology at Mayo Clinic. He assumed his current position as Deputy Director of Clinical Affairs for the Mayo Clinic Cancer Center in 2004.
Dr. Erlichman's research interests include the study of novel therapeutics in the laboratory and translating them into clinical trials. In addition, his research has focused on the development of novel therapies in the treatment of cancer with a particular emphasis on malignancies of the gastrointestinal tract. In that capacity he was a leader in developing a chemotherapy regimen that was proven to be effective in the treatment of colon cancer through the execution of multicenter, multinational clinical trials. Dr. Erlichman's expertise and experience has resulted in his serving on a number of NCI review groups and his appointment as associate editor for 3 medical journals. Currently, Dr. Erlichman has taken on the leadership of a consortium of academic medical to perform Phase II clinical trials of novel agents in patients with cancer. This NCI-funded consortium has tested a number of novel therapeutic agents in patients with various cancers. He is also the principal investigator on the Mayo Cancer Center Phase I grant leading the phase I activity in the Cancer Center. His laboratory focus began with studies of inhibitors of thymidylate synthase combined with cytotoxic nucleosides. Subsequently, studies of topoisomerase I inhibitors and inhibitors of receptors such as EGFR and IGFR1 have been pursued. Studies of CI1033 (an EGFR tyrosine kinase inhibitor) combined with topoisomerase I inhibitors revealed a novel mechanism of action for CI1033. Currently, Dr. Erlichman is studying the mechanism of action of heat shock protein 90 (HSP90) targeted agents. Geldanamycin (GA) binds to HSP90 interfering with its function and results in disruption of multiple signaling pathways involved in tumor growth and in cell cycle regulatory molecule actions. The effects on downstream proteins caused by HSP90 disruption and the interaction of GA with chemotherapy are being studied. These preclinical studies which elucidated the impact of HSP90 targeting on tumor cells have led to phase I and phase II clinical trials of its analog 17-AAG alone and in combination with chemotherapy.
See my publications
- Professor of Oncology
- Fellow American College of Physicians
- Visiting Fellow - Clinical Pharmacology National Cancer Institute, National Institutes of Health
- Resident - Medical Oncology Princess Margaret Hospital
- Chief Resident - Medical Oncology Princess Margaret Hospital
- Resident - Medicine Toronto Western Hospital
- Internship - Medicine Mount Sinai Hospital
- MD University of Toronto
- BSc University of Toronto